Genentech Bolsters Investment in Holly Springs Facility

In a significant boost to its U.S. operations, Genentech, part of the Roche Group, is set to more than double its investment in its Holly Springs, North Carolina facility to around $2 billion. This expansion not only underscores Genentech’s confidence in the region’s potential but is also poised to produce over 2,000 jobs, catalyzing economic and industry growth.

Genentech’s expansion in Holly Springs highlights its commitment to enhancing its U.S.-based manufacturing footprint, particularly on the East Coast. The facility, which began construction in August 2025, is anticipated to become operational by 2029. It will employ advanced biomanufacturing techniques to produce next-generation treatments for metabolic conditions, including obesity. This move is perfectly aligned with Genentech’s overarching strategy to fortify its U.S. supply chain and underscores the company’s dedication to innovation and sustainability. By generating 500 high-wage manufacturing positions and 1,500 construction jobs, the investment underscores the significance of the Raleigh-Durham area as a burgeoning hub for biopharmaceutical innovation.

This expanded investment by Genentech in Holly Springs emphasizes the company’s long-term vision for growth and innovation in the biopharmaceutical industry. With support from local and state authorities, and leveraging the region’s skilled workforce and strong infrastructure, Genentech’s initiative is set to become a pivotal component of Roche’s $50 billion commitment to U.S. manufacturing. This advancement stands to strengthen Genentech’s position as a key driver of economic and healthcare advancements.